عنوان

The practice of medicinal chemistry /

شابک

0124172059

شابک

9780124172050

شماره

dltt

عنوان اصلي

The practice of medicinal chemistry /

نام عام مواد

[Book]

نام نخستين پديدآور

edited by Camille Georges Wermuth, David Aldous, Pierre Raboisson, Didier Rognan

وضعيت ويراست

Fourth edition

نام خاص و کميت اثر

xxii, 880 pages :

ساير جزييات

illustrations ;

ابعاد

29 cm

متن يادداشت

Includes bibliographical references and index

متن يادداشت

Machine generated contents note: I.General Aspects Of Medicinal Chemistry -- 1.Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems / Peter Imming -- I.Definitions and Objectives -- II.Drug Activity Phases -- III.Drug Classification Systems -- References -- 2.Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies / John Unitt -- I.Introduction -- II.Drug Discovery Approaches and Screening Cascades -- III.In Vitro Assays -- IV.Ex Vivo Assays -- V.In Vivo Assays -- Acknowledgements -- References -- 3.Drug Targets, Target Identification, Validation, and Screening / Walter M.M. Van Den Broeck -- I.Introduction -- II.What is a Drug Target? -- III.The Purpose of Target Identification -- IV.Target Options and Treatment Options -- V.Target Deconvolution and Target Discovery -- VI.Methods for Target Identification and Validation -- VII.Target Validation -- VIII.Conclusion -- References --

متن يادداشت

Note continued: 31.Improving the Water-Solubility of Compounds by Molecular Modification to Disrupt Crystal Packing / Yuichi Hashimoto -- I.Introduction -- II.Rationale for Disruption of Crystal Packing as an Alternative Method to Improve Solubility -- III.Improvement of Solubility by Disrupting Intermolecular Hydrogen Bonds -- IV.Improvement of Solubility by Disrupting Molecular Planarity -- V.Improvement of Solubility by Bending the Molecular Structure -- VI.Advantages of Improving Solubility by Molecular Modification to Weaken Intermolecular Interaction -- VII.Conclusion -- References -- 32.Chemical and Physicochemical Approaches to Solve Formulation Problems / N. Murti Vemuri -- I.Introduction -- II.Stability -- III.Bioavailability -- IV.Modifying the Duration of Action -- V.Manufacturing Issues -- VI.Adapting to Patient's Needs -- References -- 33.Discover a Drug Substance, Formulate, and Develop It to a Product / Bernard Faller -- I.Introduction --

متن يادداشت

Note continued: 6.In Silico Screening: Hit Finding from Database Mining / Gisbert Schneider -- I.Introduction -- II.In Silico Screening -- III.De Novo Design -- IV.Conclusions and Future Directions -- Glossary -- References -- 7.Fragment-Based Drug Discovery / Allen B. Reitz -- I.Ligand -- Protein Interactions: First Principles -- II.What is Fragment-Based Drug Discovery? -- III.Creation and Analysis of FBDD Libraries -- IV.Fragment Screening Methods -- V.Other Biochemical and Biophysical Methods -- VI.Fragment Merging/Linking/Growing -- VII.Fragment Hit Follow-Up, and Pitfalls to Avoid -- VIII.Zelboraf®, First Approved Drug from FBDD -- IX.Limitations of FBDD -- X.Trends for the Future -- References -- 8.Molecular Variations Based on Isosteric Replacements / Bruno Giethlen -- I.Introduction -- II.History: Development of the Isosterism Concept -- III.Currently Encountered Isosteric and Bioisosteric Modifications -- IV.Scaffold Hopping --

متن يادداشت

Note continued: I.Introduction -- II.Case Studies -- III.Summary and Outlook -- References -- 12.Application Strategies for the Primary Structure -- Activity Relationship Exploration / Jean-Philippe Rocher -- I.Introduction -- II.Preliminary Considerations -- III.Hit Optimization Strategies -- IV.Application Rules -- References -- 13.Substituent Groups / Camille G. Wermuth -- I.Introduction -- II.Methyl Groups -- III.Effects of Unsaturated Groups -- IV.Effects of Halogenation -- V.Effects of Hydroxylation -- VI.Effects of Thiols and Other Sulfur-Containing Groups -- VII.Acidic Functions -- VIII.Basic Groups -- IX.Attachment of Additional Binding Sites -- References -- 14.The Role of Functional Groups in Drug -- Receptor Interactions / Laurent Schaeffer -- I.Introduction -- II.General Principles -- III.The Importance of the Electrostatic and Steric Match Between Drug and Receptor -- IV.The Strengths of Functional Group Contributions to Drug -- Receptor Interactions --

متن يادداشت

Note continued: II.Lead Compound Discovery Strategies -- 4.Strategies in the Search for New Lead Compounds or Original Working Hypotheses / Jean-Philippe Rocher -- I.Introduction -- II.First Strategy: Analog Design -- III.Second Strategy: Systematic Screening -- IV.Third Strategy: Exploitation of Biological Information -- V.Fourth Strategy: Planned Research and Rational Approaches -- VI.Fifth Strategy: Applying Biophysical Technologies and Computational Methods -- VII.Conclusion -- References -- 5.Natural Products as Pharmaceuticals and Sources for Lead Structures / David G.I. Kingston -- I.Introduction -- II.The Importance of Natural Products in Drug Discovery and Development -- III.The Design of an Effective Natural-Products-Based Approach to Drug Discovery -- IV.Examples of Natural Products or Analogues as Drugs -- V.Future Directions in Natural Products as Drugs and Drug Design Templates -- VI.Summary -- References --

متن يادداشت

Note continued: II.The Discovery Phase -- III.Defining Experimental Formulations, the Creative Phase -- IV.Preparation for a New Drug-Product Launch -- V.Conclusion: Drug Discovery and Development in Industry -- Reference -- VII.Pharmaceutical And Chemical Means To Solubility And Formulation Problems -- 34.Drug Nomenclature / Sabine Kopp -- I.Introduction -- II.Trade Names and Nonproprietary Names -- III.Drug Nomenclature -- IV.Use and Protection of Nonproprietary Names -- V.Summary -- References -- Annex -- 35.Web Alert: Using the Internet for Medicinal Chemistry / David Cavalla -- I.Introduction -- II.Blogs -- III.Wikis -- IV.Compound Information -- V.Biological Properties of Compounds -- VI.Drug Information -- VII.Physical Chemical Information -- VIII.Prediction and Calculation of Molecular Properties -- IX.Chemical Suppliers -- X.Chemical Synthesis -- XI.Chemoinformatics Software Programs -- XII.Chemical Analysis -- XIII.Chemical Publications --

متن يادداشت

Note continued: III.Advanced Approaches -- IV.Application Study: Novel Histamine H3-Receptor Antagonists -- V.Recent Developments and Outlook -- VI.Conclusions -- References -- 22.Protein Crystallography and Drug Discovery / Herman Schreuder -- I.Introduction -- II.Historical Background -- III.Basic Principles and Methods of Protein Crystallography -- IV.Applications -- V.Two Selected Examples -- VI.Outlook -- References -- 23.Physiological Aspects Determining the Pharmacokinetic Properties of Drugs / Johan Van De Voorde -- I.Introduction -- II.Passage of Drugs Through Biological Barriers -- III.Drug Absorption -- IV.Drug Distribution -- V.Drug Elimination -- VI.Some Pharmacokinetic Parameters and Terminology -- VII.Variability in Pharmacokinetics -- Further Reading -- 24.Biotransformation Reactions and their Enzymes / Bernd Clement -- I.Introduction -- II.Functionalization Reactions -- III.Conjugation Reactions -- IV.Biological Factors Influencing Drug Metabolism --

متن يادداشت

Note continued: III.Optical Isomerism and Pharmacodynamic Aspects -- IV.Optical Isomerism and Pharmacokinetic Aspects -- V.Practical Considerations -- References -- 19.Multitarget Drugs: Strategies and Challenges for Medicinal Chemists / Zoran Rankovic -- I.Introduction -- II.Strategies for Lead Generation -- III.Main Areas of Focus in Discovery -- IV.Optimization of the Activity Profile and Wider Selectivity -- V.The Physicochemical Challenge -- VI.Summary -- References -- 20.Selective Optimization of Side Activities (SOSA) in Drug Discovery / Tim Jonckers -- I.Introduction -- II.Ritonavir: Rejuvenating a Suboptimal Drug -- III.Sildenafil, Side Effects are Not Always Bad -- IV.Nucleotide Prodrugs: Chemical Trojan Horses -- V.Miltefosine -- VI.Aztreonam -- VII.Conclusions -- References -- V.Spatial Organization, Receptor Mapping And Molecular Modeling -- 21.Pharmacophore Identification and Pseudo-Receptor Modeling / Wolfgang Sippl -- I.Introduction -- II.Methodology --

متن يادداشت

Note continued: References -- 28.Designing Prodrugs and Bioprecursors / Camille G. Wermuth -- I.Introduction -- II.The Different Kinds of Prodrugs -- III.Practical Applications of Carrier Prodrugs -- IV.Unique Approaches to Carrier Prodrug Design -- V.Bioprecursor Prodrug Examples -- VI.Discussion -- VII.Difficulties and Limitations -- VIII.Conclusion -- References -- VI.Chemical Modifications Influencing The Pharmacokinetic Properties -- 29.Drug Delivery with Organic Solvents or Colloidal Dispersed Systems / Bernd U. Riebesehl -- I.Introduction -- II.Physicochemical Drug Properties -- III.Oral Drug Delivery -- IV.Parenteral Drug Delivery -- References -- 30.Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties / Dominique Lesuisse -- I.Introduction -- II.Solubilization Strategies -- III.Acidic Solubilizing Chains -- IV.Basic Solubilizing Chains -- V.Nonionizable Side Chains -- VI.Concluding Remarks -- References --

متن يادداشت

Note continued: V.Analysis of the Modifications Resulting from Isosterism -- VI.Minor Metalloids-Toxic Isosteres -- References -- 9.Ring Transformations / Camille G. Wermuth -- I.Introduction -- II.Analogical Approaches -- III.Disjunctive Approaches -- IV.Conjunctive Approaches -- V.Conclusion -- References -- 10.Macrocycles: Under-Explored and Poorly Exploited Drug Class Despite the Proven Therapeutic Potential / Pierre Raboisson -- I.Nature as a Source of Macrocycles -- II.Identification of Macrocyclic Drugs Using Either Phenotypic Screen or Target-Based Approach -- III.Macrocycles: The Drugs in the Middle Space -- IV.Effect of the Macrocyclization on Drug-Like Properties -- V.Interaction of Macrocycles with their Targets -- VI.Synthesis of Macrocycles & Library Enrichment -- VII.Conclusion -- References -- III.Primary Exploration Of Structure-Activity Relationships -- 11.Conformational Restriction and Steric Hindrance in Medicinal Chemistry / Andre Mann --

متن يادداشت

Note continued: V.Cooperative Binding -- References -- 15.Compound Properties and their Influence on Drug Quality / Thierry Kogej -- I.Introduction -- II.Compound Drug-Likeness Analysis -- III.Compound Promiscuity -- IV.Compound ADMET Properties -- V.Ligand Binding Efficiency Metrics -- VI.Conclusions and Future Outlook -- References -- 16.Pharmacological Space / Andrew L. Hopkins -- I.What is Pharmacological Space? -- II.Chemical Space -- III.Target Space -- IV.Conclusions -- Acknowledgments -- References -- 17.Systems Biology: A New Paradigm for Drug Discovery / Olivier Taboureau -- I.Introduction -- II.Drug-Target Space (off-target) -- III.Systems Biology Space -- IV.Phenotype Space -- V.Examples -- VI.Conclusion -- References -- IV.Substituents And Functions: Qualitative Aspects Of Structure-Activity Relationships -- 18.Optical Isomerism in Drugs / Camille G. Wermuth -- I.Introduction -- II.Experimental Facts and their Interpretation --

متن يادداشت

Note continued: V.What is the Relative Significance of These Many Types of Metabolic Reactions? -- VI.Concluding Remarks -- References -- 25.Biotransformations Leading to Toxic Metabolites: Chemical Aspects / Patrick M. Dansette -- I.Historical Background -- II.Introduction -- III.Reactions Involved in Bioactivation Processes -- IV.Examples of Metabolic Conversions Leading to Toxic Metabolites -- V.Conclusion -- Acknowledgments -- References -- 26.Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs / Jean-Michel Scherrmann -- I.Introduction -- II.Biology and Function of Transporters -- III.Transporters in Drug Disposition -- IV.Roles of Transporters in Drug Pharmacokinetics, Pharmacodynamics and Toxicology -- V.Conclusion -- Acknowledgments -- References -- 27.Strategies for Enhancing Oral Bioavailability and Brain Penetration / Gerhard Gross -- I.Introduction -- II.Enhancing Oral Bioavailability -- III.Enhancing Brain Penetration --

متن يادداشت

Note continued: XIV.Patent Information -- XV.Toxicology -- XVI.Meta-Sites and Technology Service Provider Databases -- XVII.Conclusion -- 36.Protection of Inventions in Medicinal Chemistry / Christopher Brice -- I.Patents and the Medicinal Chemist -- II.What Kinds of Medical Inventions can be Patented? -- III.The Basics of Patent Law -- IV.The Role of the Medicinal Chemist in the Patent Arena -- V.Patents as a Source of Scientific Information -- VI.Other Forms of Protection -- VII.Conclusion

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

موضوع مستند نشده

Drugs-- Design

موضوع مستند نشده

Pharmaceutical chemistry

موضوع مستند نشده

Chemistry, Pharmaceutical

موضوع مستند نشده

Models, Chemical

موضوع مستند نشده

Pharmaceutical Preparations-- chemistry

شماره

ويراست

شماره رده

نشانه اثر

شماره رده

شماره رده

مستند نام اشخاص تاييد نشده

Aldous, David, (David John)

مستند نام اشخاص تاييد نشده

Raboisson, Pierre

مستند نام اشخاص تاييد نشده

Rognan, Didier

مستند نام اشخاص تاييد نشده

Wermuth, C. G.

تاريخ عمليات

20160811023149.0

قواعد فهرست نويسي ( بخش توصيفي )

rda

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y